Robert E. Merritt
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · 168 works · 5,142 citations · h-index 35
Top works
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
- Small Cell Lung Cancer
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- Targeting calcium signaling in cancer therapy
- NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018
- Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer
- Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).
- Hospital cost and clinical effectiveness of robotic-assisted versus video-assisted thoracoscopic and open lobectomy: A propensity score–weighted comparison
- Propensity-score adjusted comparison of pathologic nodal upstaging by robotic, video-assisted thoracoscopic, and open lobectomy for non–small cell lung cancer
- Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis
- A Dominant Adenocarcinoma With Multifocal Ground Glass Lesions Does Not Behave as Advanced Disease
- Morbidity and Mortality After Esophagectomy Following Neoadjuvant Chemoradiation
- NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022
- Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancer
- Long-Term Oncologic Outcomes After Robotic Lobectomy for Early-stage Non–Small-cell Lung Cancer Versus Video-assisted Thoracoscopic and Open Thoracotomy Approach
- Understanding the financial cost of robotic lobectomy: calculating the value of innovation?
- Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer
- Computed Tomography-Assessed Skeletal Muscle Mass as a Predictor of Outcomes in Lung Cancer Surgery
- PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis